A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Conditions
Acute Lymphoblastic Leukemia · Philadelphia Chromosome · Philadelphia-Positive ALL · Adult ALL · IKZF1 Gene Mutation
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Dept of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Study leads
Hongsheng Zhou, M.D., Ph.D
Principal Investigator
Department of Hematology Nanfang Hospital
Zhixiang Wang, M.D., Ph.D
Study Director
Department of Hematology Nanfang Hospital
Ting Zhang, M.D., Ph.D
Study Director
Department of Hematology Nanfang Hospital
Ren Lin, M.D., Ph.D
Study Director
Department of Hematology Nanfang Hospital
Congcong Wang
Study Director
Department of Hematology Nanfang Hospital
Jiali Yao
Study Director
Department of Hematology Nanfang Hospital
Qianwei Liu, Ph.D
Study Director
Department of Hematology Nanfang Hospital